Patrick Campbell
Associate Editorial Director at HCP Live
Director: @HCPLiveNews, @ContempPeds, @ContempOBGYN, & @UrologyTimes. Producer: #DiabetesDialogue, #DontMissABeat, #KidneyCompass. Opinions are my own. #Ramily
Articles
-
4 days ago |
hcplive.com | Patrick Campbell
Results of the phase 4 CATALYST trial indicate mifepristone (Korlym) significantly improved glycemic control, reduced body weight, and decreased waist circumference in patients with hypercortisolism and type 2 diabetes—offering a promising new strategy for a population with limited therapeutic success.
-
4 days ago |
hcplive.com | Patrick Campbell
A new trial from the 85th Scientific Sessions of the American Diabetes Association (ADA 2025) provides evidence of a once-monthly agent that could be a game-changer for management of obesity and type 2 diabetes. Results of the phase 2 trial of maridebart cafraglutide, also known as MariTide, indicate use was associated with body weight reductions ranging from 12-16% in obesity to 8.4-12% in type 2 diabetes with obesity.
-
5 days ago |
hcplive.com | Patrick Campbell
For people with type 2 diabetes starting insulin therapy, a once-weekly insulin named efsitora alfa is just as effective in lowering blood glucose as a daily regimen with daily basal insulin, according to a new study.
-
5 days ago |
hcplive.com | Patrick Campbell
A global study suggests expanding access to semaglutide could save 28 million lives globally over the next 5 years. Results of the study, which were presented at the 85th Scientific Sessions of the American Diabetes Association (ADA 2025), suggest universal access could significantly reduce the burden of type 2 diabetes, obesity, and related health outcomes worldwide.
-
5 days ago |
hcplive.com | Patrick Campbell
Data from REDEFINE 1 and REDEFINE 2 indicate coadministration of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema) was associated with weight reductions in the highest range of existing weight loss interventions.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 715
- Tweets
- 8K
- DMs Open
- No
RT @HCPLiveNews: Doctors @MasriAhmadMD, @DorbalaSharmila, @abouezzeddine, @premsoman123 & Daniel Judge highlight how evolving ATTR-CM treat…
RT @UNCurology: 🎥 Don’t miss this exclusive interview with @DrMBWesterman on the latest survey findings in NMIBC treatment. She breaks dow…
RT @brendonneuen: Baseline use of #SGLT2i in recent trials enrolling patients with #IgAN: Listen to the full podcast discussion between me…
